These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 29753401)

  • 21. Vitamin D and Cardiovascular Complications of CKD: What's Next?
    Banerjee D; Jha V
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):932-934. PubMed ID: 31064752
    [No Abstract]   [Full Text] [Related]  

  • 22. Vitamin D and cardiovascular disease in chronic kidney disease.
    Kaur G; Singh J; Kumar J
    Pediatr Nephrol; 2019 Dec; 34(12):2509-2522. PubMed ID: 30374603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D and cardiovascular prevention.
    Nadir MA; Szwejkowski BR; Witham MD
    Cardiovasc Ther; 2010 Aug; 28(4):e5-12. PubMed ID: 20553279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease.
    Hénaut L; Chillon JM; Kamel S; Massy ZA
    Semin Nephrol; 2018 May; 38(3):233-250. PubMed ID: 29753400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cardioprotective effect of vitamin D in nondialyzed patients with stage 3-5 CKD].
    Cozzolino M; Mehmeti F; Bonelli F; Ronga C; Musetti C; Missaglia E; Stucchi A; Colombo F; Tavecchia M; Cuoccio P; Brenna I; Volpi E; Ciceri P; Cusi D
    G Ital Nefrol; 2010; 27 Suppl 52():S27-31. PubMed ID: 21132659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Diseases and Fat Soluble Vitamins: Vitamin D and Vitamin K.
    Tsugawa N
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S170-2. PubMed ID: 26598844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
    Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
    Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of oral calcimimetics on cardiovascular events.].
    Hamano T
    Clin Calcium; 2017; 27(4):529-535. PubMed ID: 28336829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of vitamin D in the pathogenesis of chronic kidney disease].
    Cozzolino M; Brunini F; Capone V; Ricca F; Kwaidri Y; Montanari E; Cusi D
    Recenti Prog Med; 2013 Jan; 104(1):33-40. PubMed ID: 23439539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D deficiency and its correlations with increased cardiovascular incidences.
    Sood A; Arora R
    Am J Ther; 2010; 17(4):e105-9. PubMed ID: 19451805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal osteodystrophy in children: a systemic disease associated with cardiovascular manifestations.
    Langman CB; Brooks ER
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S79-83. PubMed ID: 16624609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.
    Bover J; Ureña-Torres P; Górriz JL; Lloret MJ; da Silva I; Ruiz-García C; Chang P; Rodríguez M; Ballarín J
    Nefrologia; 2016; 36(6):597-608. PubMed ID: 27595517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C; Zitt E
    Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D therapy for chronic kidney disease.
    Bhan I; Thadhani R
    Semin Nephrol; 2009 Jan; 29(1):85-93. PubMed ID: 19121478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
    Gutiérrez OM
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D: a cardioprotective agent?
    Liss Y; Frishman WH
    Cardiol Rev; 2012; 20(1):38-44. PubMed ID: 22143284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis.
    Ruderman I; Holt SG; Hewitson TD; Smith ER; Toussaint ND
    Semin Dial; 2018 Sep; 31(5):487-499. PubMed ID: 29733462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on vascular calcification and potential therapeutics.
    Singh A; Tandon S; Tandon C
    Mol Biol Rep; 2021 Jan; 48(1):887-896. PubMed ID: 33394226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.